Neurogene Inc. Cash Flow Statement
NGNE|4 years of annual SEC 10-K data (FY2018-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 4 fiscal years. All figures from audited SEC 10-K filings.
Neurogene Inc. used $71M in operating cash flow and negative free cash flow of $71M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.24 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2019 | FY2018 |
|---|---|---|---|---|
| Net Income | -$75.1M | -$36.3M | -$50.2M | -$37.0M |
| Depreciation & Amortization | $3.2M | $3.3M | $360.0K | - |
| Operating Cash Flow | -$70.6M | -$51.4M | -$44.7M | -$30.2M |
| Capital Expenditures | $808.0K | $321.0K | $494.0K | $713.0K |
| Free Cash Flow | -$71.4M | -$51.7M | -$45.2M | -$30.9M |
| FCF Margin | -7720.1% | - | -180.8% | -123.8% |